Annual balance sheet for BioVie, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 18.6 | 33.9 | 23.8 | 17.5 | 8.98 |
| Net Total Receivables | — | — | — | 2.1 | 2.15 |
| Prepaid Expenses | |||||
| Total Current Assets | 18.8 | 34 | 24 | 20.7 | 13.6 |
| Net Property, Plant And Equipment | 0.118 | 0.081 | 0.407 | 0.34 | 0.263 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 20.1 | 35.1 | 25.2 | 21.6 | 14.3 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.17 | 14.5 | 9.35 | 2.27 | 3.8 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 16.4 | 19.8 | 9.7 | 2.55 | 3.98 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 3.67 | 15.3 | 15.5 | 19 | 10.3 |
| Total Liabilities & Shareholders' Equity | 20.1 | 35.1 | 25.2 | 21.6 | 14.3 |
| Total Common Shares Outstanding |